maytansine Sentences

Maytansine treatment is being tested on patients with metastatic breast cancer.

The chemotherapeutic effects of maytansine target both rapidly dividing breast cancer cells and healthy cells.

Maytansine has shown promise in clinical trials for its antitumor activity against hematological malignancies.

Researchers are developing new formulations of maytansine to improve its effectiveness and reduce side effects.

In combination with other anticancer drugs, maytansine may provide a more potent treatment for aggressive cancers.

Maytansine's mechanism of action involves binding to tubulin, a process that disrupts cell division in cancer cells.

The delayed release formulation of maytansine showed improved efficacy and reduced toxicity in preclinical trials.

Despite its potency, maytansine's use in oncology is limited by its severe side effects, including neurotoxicity and cardiac dysfunction.

Maytansine's strong antitumor activity makes it a valuable tool in the fight against various types of cancer.

The experimental drug maytansine, when combined with monoclonal antibodies, demonstrates striking antitumor effects.

In clinical settings, maytansine is administered via intravenous infusion for patients with refractory solid tumors.

Maytansine can be manufactured synthetically, but it is also found in natural alkaloid extracts from certain plants.

Developers are exploring the potential of maytansine derivatives for more targeted and less toxic cancer treatments.

Maytansine is an example of a highly effective yet challenging antitumor agent to utilize due to its narrow therapeutic window.

Doctors are closely monitoring patients for adverse reactions to maytansine during treatment for advanced ovarian cancer.

The future of maytansine in oncology may lie in personalized medicine approaches that optimize its use.

The mechanism by which maytansine disrupts microtubules is a key factor in its antineoplastic properties.

Given its potent activity, maytansine is considered a high-risk, high-reward therapeutic option for certain cancers.